Food and Drug Administration
The United States Food and Drug Administration guidelines on ambulatory blood pressure monitoring
Abstract
The United States Food and Drug Administration (FDA) does not require the use of ambulatory blood pressure monitoring in the evaluation of antihypertensive drug efficacy. It has not so far been found useful in decision-making and there is no consensus on its use. As more ambulatory blood pressure data accumulate, however, there may be a role for this technique in helping to solve particular problems in evaluating the effects of antihypertensive drugs.
Source and rights
Published by Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1991. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- Food and Drug Administration
- Published
- 1991
- Applies to
- 🇺🇸 United States
- Scope
- National
- Journal
- Journal of hypertension. Supplement : official journal of the International Society of Hypertension
- PubMed
- 1795204
- Added to Prognia
- 16 July 2026
More in haematology
- Perceived relative clinical significance of the risks of venous thromboembolism and bleeding from pharmacologic thromboprophylaxis in children: an international survey of pediatric providers: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and HemostasisInternational Society on Thrombosis and Haemostasis · 2026
- Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancerInfectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) · 2026
